4.5 (542) In stock
A Barbara Ann Karmanos Cancer Institute clinical researcher and her team have received $16,000 to further research in precision medicine for breast cancer treatment. Common Citizen leadership delivered the check to Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer and Phase 1 Clinical Trials Multidisciplinary Teams, in November 2023. Dr. Elayoubi and her team have made significant strides in studying biomarkers and tumor molecular characteristics that may predict sensitivity and
Company Profile: HistoRx: tissue-based diagnostic solutions for
Barbara Ann Karmanos Cancer Institute
Cells, Free Full-Text
Karmanos Cancer Institute on LinkedIn: #yourbestchance #onepride
Discovery of primary prostate cancer biomarkers using cross cancer
Karmanos Cancer Institute
Cancers, Free Full-Text
Biomarkers in Precision Medicine with Special Reference to
ncRNA, Free Full-Text
Making Biomarkers Relevant to Healthcare Innovation and Precision
Karmanos Cancer Institute on LinkedIn: #yourbestchance
IN THE NEWS: Karmanos Cancer Institute Expands into Ohio
Karmanos Cancer Institute
PROMISE: a real-world clinical-genomic database to address
Karmanos Cancer Institute - Cancer treatment in Michigan and Ohio
